{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Virus+Infection%2C+RNA&page=34", "query": { "condition": "Virus Infection, RNA", "page": 34 }, "page_size": 10 }, "pagination": { "page": 34, "page_size": 10, "total_count": 7828, "total_pages": 783, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Virus+Infection%2C+RNA&page=35&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Virus+Infection%2C+RNA&page=33&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T17:46:20.850Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00000766", "title": "CMV Retinitis Retreatment Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cytomegalovirus Retinitis", "HIV Infections" ], "interventions": [ { "name": "Foscarnet sodium", "type": "DRUG" }, { "name": "Ganciclovir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2011-03-01", "last_synced_at": "2026-10-17T17:46:20.850Z", "location_count": 9, "location_summary": "La Jolla, California • Los Angeles, California • San Francisco, California + 4 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000766" }, { "nct_id": "NCT05016622", "title": "Booster Dose Trial", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "BNT162b2 vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Montefiore Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 106, "start_date": "2021-08-10", "completion_date": "2023-05-21", "has_results": true, "last_update_posted_date": "2024-07-31", "last_synced_at": "2026-10-17T17:46:20.850Z", "location_count": 1, "location_summary": "The Bronx, New York", "locations": [ { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05016622" }, { "nct_id": "NCT04665245", "title": "Symptom-Based Markers for COVID-19 Transmission", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Covid19" ], "interventions": [], "intervention_types": [], "sponsor": "University of Iowa", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 214, "start_date": "2020-12-15", "completion_date": "2021-05-19", "has_results": true, "last_update_posted_date": "2026-01-26", "last_synced_at": "2026-10-17T17:46:20.850Z", "location_count": 1, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT04665245" }, { "nct_id": "NCT01088295", "title": "HIV and Fat Accumulation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infection" ], "interventions": [ { "name": "Telmisartan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2010-05", "completion_date": "2011-06", "has_results": true, "last_update_posted_date": "2019-02-04", "last_synced_at": "2026-10-17T17:46:20.850Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01088295" }, { "nct_id": "NCT00812019", "title": "Dose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18-40 Years Old)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Influenza" ], "interventions": [ { "name": "Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_0%MF59", "type": "BIOLOGICAL" }, { "name": "Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_25%MF59", "type": "BIOLOGICAL" }, { "name": "Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_50%MF59", "type": "BIOLOGICAL" }, { "name": "Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_100%MF59", "type": "BIOLOGICAL" }, { "name": "Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_0%MF59", "type": "BIOLOGICAL" }, { "name": "Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_25%MF59", "type": "BIOLOGICAL" }, { "name": "Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_50%MF59", "type": "BIOLOGICAL" }, { "name": "Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_100%MF59", "type": "BIOLOGICAL" }, { "name": "Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_0%MF59", "type": "BIOLOGICAL" }, { "name": "Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_25%MF59", "type": "BIOLOGICAL" }, { "name": "Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_50%MF59", "type": "BIOLOGICAL" }, { "name": "Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_100%MF59", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Seqirus", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "18 Years to 40 Years" }, "enrollment_count": 753, "start_date": "2008-11", "completion_date": "2010-11", "has_results": false, "last_update_posted_date": "2020-08-24", "last_synced_at": "2026-10-17T17:46:20.850Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00812019" }, { "nct_id": "NCT04358081", "title": "Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Covid-19" ], "interventions": [ { "name": "HCQ", "type": "DRUG" }, { "name": "HCQ+AZT", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2020-05-01", "completion_date": "2020-07-27", "has_results": true, "last_update_posted_date": "2021-10-11", "last_synced_at": "2026-10-17T17:46:20.850Z", "location_count": 7, "location_summary": "Fullerton, California • Los Angeles, California • Chicago, Illinois + 4 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baton Rouge", "state": "Louisiana" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04358081" }, { "nct_id": "NCT06370481", "title": "HIV, Equity, and Addiction Training (HEAT) Program", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Substance Use Disorders", "Hiv", "Opioid Use Disorder", "Stimulant Use (Diagnosis)" ], "interventions": [ { "name": "Telemedicine", "type": "OTHER" }, { "name": "Standard of care", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2026-01-29", "completion_date": "2029-06", "has_results": false, "last_update_posted_date": "2026-02-18", "last_synced_at": "2026-10-17T17:46:20.850Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT06370481" }, { "nct_id": "NCT00000919", "title": "A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Indinavir sulfate", "type": "DRUG" }, { "name": "Lamivudine/Zidovudine", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "Hydroxyurea", "type": "DRUG" }, { "name": "Abacavir sulfate", "type": "DRUG" }, { "name": "Amprenavir", "type": "DRUG" }, { "name": "Nelfinavir mesylate", "type": "DRUG" }, { "name": "Efavirenz", "type": "DRUG" }, { "name": "Lamivudine", "type": "DRUG" }, { "name": "Stavudine", "type": "DRUG" }, { "name": "Zidovudine", "type": "DRUG" }, { "name": "Didanosine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 900, "start_date": null, "completion_date": "2002-11", "has_results": false, "last_update_posted_date": "2012-06-07", "last_synced_at": "2026-10-17T17:46:20.850Z", "location_count": 63, "location_summary": "Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 37 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Menlo Park", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000919" }, { "nct_id": "NCT00262483", "title": "Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "VX-950", "type": "DRUG" }, { "name": "ribavirin", "type": "DRUG" }, { "name": "peginterferon alfa-2a", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 12, "start_date": "2005-12", "completion_date": "2006-04", "has_results": false, "last_update_posted_date": "2007-12-21", "last_synced_at": "2026-10-17T17:46:20.850Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00262483" }, { "nct_id": "NCT03960541", "title": "Efprezimod Alfa (CD24Fc, MK-7110) Administration to Decrease Low-Density Lipoprotein (LDL) and Inflammation in Human Immunodeficiency Virus (HIV) Patients (CALIBER) (MK-7110-003)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections", "Dyslipidemias" ], "interventions": [ { "name": "Efprezimod alfa (human CD24 extracellular domain and human IgG1 Fc fusion protein)", "type": "DRUG" }, { "name": "Saline Solution", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 8, "start_date": "2020-08-31", "completion_date": "2021-05-27", "has_results": true, "last_update_posted_date": "2023-02-08", "last_synced_at": "2026-10-17T17:46:20.850Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03960541" } ] }